Sugi Predict

Sugi Predict / Compounds / SCHEMBL7311829

SCHEMBL7311829

SCHEMBL7311829

COC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KLK5 Q9Y337 1/20 0.53
▸ PEPD P12955 2/20 0.48
▸ XPNPEP1 Q9NQW7 1/20 0.48
▸ FKBP1A P62942 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ CMA1 P23946 7/20 0.44
▸ ACE P12821 1/20 0.42
▸ PREP P48147 2/20 0.42
▸ FAP Q12884 1/20 0.42
▸ KMT2A Q03164 1/20 0.40
▸ ELANE P08246 1/20 0.40
▸ CTSL P07711 2/20 0.39
▸ CTSB P07858 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28719311 1.00 KLK5 (0.53) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL14235323 1.00 KLK5 (0.53) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL28853236 1.00 KLK5 (0.53) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL17348390 1.00 KLK5 (0.53) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL12658515 0.95 KLK5 (0.52) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL30406562 0.93 KLK5 (0.46) KLK5PEPDXPNPEP1POLBCMA1
SCHEMBL15692884 0.89 PEPD (0.49) KLK5PEPDXPNPEP1FKBP1APOLB
SCHEMBL7316962 0.89 CMA1 (0.51) KLK5PEPDXPNPEP1CMA1ELANE
SCHEMBL8352620 0.89 CMA1 (0.51) KLK5PEPDXPNPEP1CMA1ELANE
SCHEMBL8168154 0.89 CMA1 (0.51) KLK5PEPDXPNPEP1CMA1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114249795-A Preparation method of enalapril maleate and intermediate thereof 佛山奕安赛医药科技有限公司 2022-03-29 — — CN claimed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
CN-114249795-A Preparation method of enalapril maleate and intermediate thereof 佛山奕安赛医药科技有限公司 2022-03-29 — — CN disclosed
CN-114249795-A Preparation method of enalapril maleate and intermediate thereof 佛山奕安赛医药科技有限公司 2022-03-29 — — CN disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
EP-2709613-B2 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2020-08-12 — — EP disclosed
US-10392422-B2 Macrocyclic broad spectrum antibiotics RQX PHARMACEUTICALS, INC. (US) 2019-08-27 — — US disclosed
US-10351595-B2 — — 2019-07-16 — — US disclosed
US-20170088582-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2017-03-30 — — US disclosed
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides EVONIK DEGUSSA GMBH (DE) 2016-09-22 — — US disclosed
WO-2015179441-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2015-11-26 — — WO disclosed
WO-2015067450-A1 CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES EVONIK INDUSTRIES AG (DE) 2015-05-14 — — WO disclosed
EP-2868643-A1 Catalytic hydrogenation for the preparation of amines from carboxylic acid amides, carboxylic acid amides, di-, tri- or polypeptides or peptide amides Evonik Industries AG (DE) 2015-05-06 — — EP disclosed
US-5583146-A Heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 — — US disclosed
EP-0601459-A2 Sulfonamido heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1994-06-15 — — EP disclosed
EP-0128602-B1 RETRO-INVERSO ANALOGUES OF THE BRADYKININ POTENTIATING PEPTIDE BPP5A AND METHOD FOR THEIR PREPARATION ENI-Ente Nazionale Idrocarburi (IT) 1990-06-27 — — EP disclosed
US-4522752-A HYPOTENSIVE AGENTS, DIAGNOSIS E.N.I. ENTE NAZIONALE IDROCARBURI (IT) 1985-06-11 — — US disclosed
EP-0128602-A2 Retro-inverso analogues of the bradykinin potentiating peptide BPP5a and method for their preparation ENI-Ente Nazionale Idrocarburi (IT) 1984-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351595-B2 — MRPL21, PRSS1, PEPD KLK5 1880/4885PEPD 3/4885XPNPEP1 19/4885
US-10392422-B2 Macrocyclic broad spectrum antibiotics MRPL21, PEPD, CTSC KLK5 2545/4885PEPD 2/4885XPNPEP1 22/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 KLK5 892/4885PEPD 64/4885XPNPEP1 1257/4885
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides DAO, DDC, HDGF KLK5 3630/4885PEPD 52/4885XPNPEP1 1480/4885
US-20170088582-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC KLK5 2545/4885PEPD 2/4885XPNPEP1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.